Previous 10 | Next 10 |
Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today announced an interview with Chairman and CEO, Greg Duncan, w...
Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that Greg Duncan, Chairman and Chief Executive Officer,...
Virios Therapeutics (VIRI): Q4 GAAP EPS of -$1.25.Cash totaled $29.8MPress Release For further details see: Virios Therapeutics reports Q4 results
Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today reported financial results for the fourth quarter and year ended ...
The company believes that an abnormal immune response to Herpes Simplex Virus 1 (HSV-1) infection is responsible for chronic conditions like FM and IBS, representing a novel mechanism of action. There is currently no significantly effective treatment for 3.6M diagnosed FM patients. ...
Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that its fourth quarter and full year 2020 financial re...
Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that Greg Duncan, Chairman and Chief Executive Officer,...
Virios Therapeutics (VIRI) rises 10% premarket in reaction to the announcement it is collaborating with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome ((IBS)).The first step in the partnership is focused on designing...
Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo C...
Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that Greg Duncan, Chairman and Chief Executive Officer, and R. Michael Gendr...
News, Short Squeeze, Breakout and More Instantly...
Virios Therapeutics Inc. Company Name:
VIRI Stock Symbol:
NASDAQ Market:
Virios Therapeutics Inc. Website:
ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibro...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 16.4% to $0.199 on volume of 720,586,242 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 74.8% to $1.8 on volume of 682,362,254 shares Pineapple Energy Inc. (PEGY) rose 80.3% to $0.1...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 37.1% to $0.2344 on volume of 300,511,226 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 78.2% to $1.835 on volume of 218,102,513 shares Greenwave Technology Solutions Inc. (GWAV) r...